Articles related to ANTISEIZURE MEDICATIONS

The study objectives were to compare the outcomes of 6-year-old children of women with epilepsy (WWE) vs those of healthy pregnant women (HW), and to assess the association of outcomes to third-trimester antiseizure medications (ASM) exposures.

After adjustment for demographic and clinical factors, cenobamate was associated with statistically significant higher odds of achieving a 50% or greater reduction in seizure frequency at 6 months vs all three comparators.

“Too many neurons go astray, and that’s when you get amyloid-beta production. And then it’s tau, and then it’s dead cells, then dementia — and then it’s too late.” — Jeffrey Savas, Northwestern University

Lamotrigine was not associated with an increased risk of ventricular arrhythmia and sudden cardiac arrest compared with levetiracetam, including among those with underlying heart disease.

Retrospective analysis of more than 1.4 million patients revealed dose-dependent cognitive risks, with younger adults experiencing substantially higher dementia and mild cognitive impairment rates.

The new guideline emphasizes early intervention and careful medication selection for pregnant patients with epilepsy, recommending lamotrigine, levetiracetam, and oxcarbazepine, while advising against valproic acid, phenobarbital, and topiramate.